Physician profile
Rafaele Calamia
NPI 1134295173
$5,396.68
in general payments reported to CMS, 2019-2025
24 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $660 · 2023: $1,379 · 2024: $1,668 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,280 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,279.93 |
| Education | $113.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $931.04 | 2022-2025 | Tremfya |
| Abbvie INC. | $896.62 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $586.44 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $554.56 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $365.23 | 2021-2025 | |
| Amgen INC. | $321.63 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $293.10 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $287.48 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $217.35 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $190.30 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $146.30 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $99.09 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.43 | 2021-2025 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $60.00 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $56.57 | 2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $56.04 | 2024-2025 | Nemluvio, Aklief |
| Pfizer INC. | $50.37 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $34.99 | 2021 | |
| Verrica Pharmaceuticals INC. | $33.68 | 2024-2025 | Ycanth |
| Botanix Sb INC | $26.33 | 2025 | Sofdra |
| Organon LLC | $22.45 | 2025 | Vtama |
| Dermira, INC. | $20.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafaele Calamia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.